Medtronic's Hugo™ Robotic System Receives FDA Approval for General Surgery Procedures

Medtronic's Hugo™ Robotic Surgery System Approved by FDA



In an exciting development for the surgical community, Medtronic plc, a renowned name in healthcare technology, has announced that the U.S. Food and Drug Administration (FDA) has granted clearance for its Hugo™ robotic-assisted surgery (RAS) system to be used in general surgical procedures. This expansion marks a significant milestone in the evolution of robotic surgery in the United States, particularly as the demand for such technologies continues to grow.

The FDA's approval encompasses a range of upper abdominal procedures which include cholecystectomy, Roux-en-Y gastric bypass, ventral hernia repair, and small bowel resections. Moreover, it also includes lower abdominal operations such as inguinal hernia and appendectomy. Combined, these procedures represent a substantial portion of annual surgeries in the U.S., amounting to approximately 3.5 million operations each year. This figure accounts for over half of all soft-tissue surgeries performed nationally, demonstrating the immense potential for the Hugo RAS system in this sector.

Medtronic has a legacy of collaboration with general surgeons for decades, and the commitment to advancing surgical techniques now extends to robotic surgery with the Hugo system. Matt Anderson, Senior Vice President and President of Medtronic’s Surgical business, emphasized how Hugo offers hospitals a practical option to tackle challenges related to capacity and patient access, simultaneously providing surgical teams with the flexibility to better meet the varying needs of patients.

As the number of health systems and hospitals adopting the Hugo RAS system continues to increase across the U.S., it’s noteworthy that the growth rate of procedures involving the Hugo RAS system is outpacing that of the broader robotic surgery market by more than double. By the end of Medtronic's fiscal year, the system is expected to surpass 50,000 procedures. Interestingly, it has been observed that general surgery accounts for the highest increase in Hugo RAS procedures conducted outside the U.S., exceeding both urology and gynecology.

The latest FDA clearance not only broadens the scope of surgical procedures that can be performed with the Hugo RAS system, but it also highlights the system's inherent modular design. This innovative design allows surgical teams to utilize only the robotic arms that are necessary for each specific procedure, thereby aligning with both the surgical technique and the patient’s anatomical requirements. Additionally, the open console feature creates an environment of collaboration between the surgeon and the operating room (OR) team, enhancing patient engagement.

Surgeons using the Hugo RAS system can also rely on Medtronic's established technology, such as the LigaSure™ RAS Maryland instrument. This advanced vessel-sealing technology has been effectively used in over 45 million open and laparoscopic procedures, further enriching the capabilities of the Hugo platform.

Dr. Francesco Bianco, a surgeon at UI Health and a professor of surgery at the University of Illinois College of Medicine, remarked on the importance of widening robotic-assisted surgical capabilities with systems like Hugo. He indicated that this expansion enables the provision of diverse treatment options, while also fostering the growth of surgical education and preparing the future generation of surgeons.

In its mission to enhance surgical precision, predictability, and personalization, Medtronic combines robotics, instruments, data, and expertise to ensure more patients worldwide benefit from advanced surgical techniques. The company's broader strategy includes distributing the Sentire™ surgical system in select international markets, reinforcing Medtronic's commitment to high-quality surgical innovations.

For those interested in the Hugo RAS system and its various applications, further information can be accessed at medtronic.com/HugoSpecialties.

In conclusion, Medtronic is poised to make significant contributions to the field of surgery with its Hugo robotic system, shaping the future of surgical interventions and patient care in ways that were once thought of as futuristic.

  • ---

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.